Masayoshi Okumi

The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment

Éric Rondeau, Marie Scully, Gema Ariceta et al. · Kidney International · 2020 · 219 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16

ABO-Incompatible Living Kidney Transplants: Evolution of Outcomes and Immunosuppressive Management

Masayoshi Okumi, Daisuke Toki, Taiji Nozaki et al. · American Journal of Transplantation · 2015 · 110 citations · Full text

Medicine, Nephrology, Surgery +17

Association between immune-related adverse events and prognosis in patients with metastatic renal cell carcinoma treated with nivolumab

Hiroki Ishihara, Toshio Takagi, Tsunenori Kondo et al. · Urologic Oncology Seminars and Original Investigations · 2019 · 95 citations

Medicine, Immunology, Oncology +14

Allosensitization Does Not Increase the Risk of Xenoreactivity to ??1,3-Galactosyltransferase Gene-Knockout Miniature Swine in Patients on Transplantation Waiting Lists

Banny S. Wong, Kazuhiko Yamada, Masayoshi Okumi et al. · Transplantation · 2006 · 80 citations · Full text

Life Sciences, Immunology, Surgery +17

Predictive Impact of Peripheral Blood Markers and C-Reactive Protein in Nivolumab Therapy for Metastatic Renal Cell Carcinoma

Hiroki Ishihara, Hidekazu Tachibana, Toshio Takagi et al. · Targeted Oncology · 2019 · 69 citations

Medicine, Immunology, Oncology +17